Cubist Systematic Strategies LLC Purchases 76,961 Shares of Astria Therapeutics, Inc. $ATXS

Key Points

• Cubist Systematic Strategies LLC increased its stake in Astria Therapeutics by 503.7%, acquiring an additional 76,961 shares, bringing its total ownership to 92,239 shares valued at $493,000.
• Several other hedge funds also significantly boosted their stakes in Astria Therapeutics, contributing to an overall institutional ownership of 98.98% of the company.
• Astria Therapeutics reported earnings of ($0.57) EPS, which exceeded analysts' expectations, and currently has a consensus rating of "Buy" with an average price target of $29.00.

Cubist Systematic Strategies LLC raised its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 503.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 92,239 shares of the biotechnology company's stock after purchasing an additional 76,961 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.16% of Astria Therapeutics worth $493,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its stake in shares of Astria Therapeutics by 19.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,762 shares of the biotechnology company's stock valued at $159,000 after buying an additional 2,878 shares during the period. Northern Trust Corp lifted its position in shares of Astria Therapeutics by 4.5% during the 4th quarter. Northern Trust Corp now owns 458,234 shares of the biotechnology company's stock valued at $4,097,000 after acquiring an additional 19,893 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Astria Therapeutics during the 4th quarter worth $50,000. Deutsche Bank AG grew its holdings in shares of Astria Therapeutics by 54.3% during the 4th quarter. Deutsche Bank AG now owns 39,744 shares of the biotechnology company's stock worth $355,000 after purchasing an additional 13,986 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Astria Therapeutics in the fourth quarter worth $159,000. 98.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ATXS shares. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Wednesday, August 13th. JMP Securities boosted their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company a "market outperform" rating in a research report on Wednesday, August 13th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Astria Therapeutics in a report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. Based on data from MarketBeat.com, Astria Therapeutics has an average rating of "Buy" and a consensus target price of $29.00.

Astria Therapeutics Trading Down 1.4%

NASDAQ ATXS traded down $0.10 on Tuesday, hitting $7.27. 389,272 shares of the company's stock were exchanged, compared to its average volume of 311,475. The stock has a 50-day moving average of $6.73 and a 200-day moving average of $5.73. Astria Therapeutics, Inc. has a 52 week low of $3.56 and a 52 week high of $12.92. The stock has a market cap of $410.32 million, a price-to-earnings ratio of -3.62 and a beta of 0.42.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.04. As a group, analysts predict that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.